Sitagliptin + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroparesis
Conditions
Gastroparesis, Diabetes Mellitus
Trial Timeline
Jul 1, 2007 → Dec 1, 2011
NCT ID
NCT00501657About Sitagliptin + Placebo
Sitagliptin + Placebo is a phase 1 stage product being developed by Merck for Gastroparesis. The current trial status is completed. This product is registered under clinical trial identifier NCT00501657. Target conditions include Gastroparesis, Diabetes Mellitus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02536248 | Phase 3 | Completed |
| NCT02256189 | Approved | Completed |
| NCT02294084 | Approved | Completed |
| NCT02015910 | Approved | Terminated |
| NCT01928199 | Approved | Completed |
| NCT01859793 | Approved | Completed |
| NCT01600703 | Phase 2/3 | Completed |
| NCT01334229 | Phase 3 | Completed |
| NCT01272583 | Pre-clinical | Completed |
| NCT00790205 | Phase 3 | Completed |
| NCT00732121 | Approved | UNKNOWN |
| NCT00660075 | Phase 3 | Completed |
| NCT00501657 | Phase 1 | Completed |
Competing Products
19 competing products in Gastroparesis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil + tadalafil + placebo | Eli Lilly | Phase 2 | 52 |
| Granisetron | Kyowa Kirin | Phase 2 | 52 |
| tadalafil | Eli Lilly | Approved | 85 |
| Mosapride + domperidone | Sumitomo Pharma | Approved | 85 |
| Cisapride + Placebo | Johnson & Johnson | Approved | 85 |
| Cisapride + Placebo | Johnson & Johnson | Approved | 85 |
| Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet | AstraZeneca | Phase 2 | 52 |
| Tegaserod | Novartis | Approved | 85 |
| Reglan ODT | UCB | Pre-clinical | 20 |
| Hemin + Albumin | Recordati | Phase 2 | 49 |
| CNSA-001 + Placebo | PTC Therapeutics | Phase 2 | 49 |
| Immediate-release omeprazole + Delayed-release omeprazole | Bausch Health | Approved | 80 |
| Velusetrag + Placebo | Theravance Biopharma | Phase 2 | 47 |
| velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo | Theravance Biopharma | Phase 2 | 47 |
| IW-9179 + Matching Placebo | Ironwood Pharmaceuticals | Phase 2 | 44 |
| VLY-686 (Tradipitant) | Vanda Pharmaceuticals | Phase 2 | 44 |
| Tradipitant | Vanda Pharmaceuticals | Phase 3 | 69 |
| Tradipitant | Vanda Pharmaceuticals | Pre-clinical | 15 |
| Tradipitant + Placebo + Open Label Tradipitant | Vanda Pharmaceuticals | Phase 3 | 69 |